
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio Inc is positioned favorably in the pharmaceutical market, particularly with its lead product, Buntanetap, which has the potential to positively modify disease progression in chronic neurodegeneration, including Alzheimer's and Parkinson's diseases. The company has reported promising interim results from its intrathecal RNAi therapy targeting amyloid precursor protein (APP), indicating a reduction in sAPP and a plan to advance to Phase 2 trials by the second half of 2025. Additionally, Annovis has noted alignment with the FDA regarding the potential filing of a new drug application based on well-executed six-month trial data, enhancing the prospects for future growth and market expansion.
Bears say
Annovis Bio Inc faces significant financing risks due to a modest cash runway, which may necessitate dilutive capital raising activities. The company's focus on creating treatments for challenging neurodegenerative diseases like Alzheimer's and Parkinson's poses additional risks, including potential trial failures related to efficacy and safety, as well as the possibility of regulatory setbacks regarding FDA approvals. Furthermore, even if the products reach the market, there is the threat of underperformance due to increased competition and pricing pressure, which could adversely impact commercial success.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares